Temporal Concept – Page 13

Sanofi tempers its OX40 expectations in asthma after mid-stage miss

5 months ago talkbio0Tagged Amlitelimab, Asthma, exacerbations, Expectations, sanofi, Subgroup A Nepoviruses, TNFRSF4 gene

Asthma, Amlitelimab, TNFRSF4 gene, sanofi, exacerbations, Subgroup A Nepoviruses, Expectations

Sanofi backs $90M financing for I&I biologic developer

5 months ago talkbio0Tagged financing characteristics, I&I, sanofi, Series

sanofi, Series, financing characteristics, II

Illumina and Tempus look beyond cancer in new AI-driven genomics deal

5 months ago talkbio0Tagged Artificial Intelligence, Cardiology discipline, Genetic Profile, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Immunology, Malignant Neoplasms, Market, Neurology speciality, Partnership

Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market

Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition

5 months ago talkbio0Tagged Camzyos, Clinical Trials, Hypertrophic Cardiomyopathy, Hypertrophic cardiomyopathy without obstruction, Myers, Obstructed

Camzyos, Hypertrophic Cardiomyopathy, Myers, Hypertrophic cardiomyopathy without obstruction, Obstructed, Clinical Trials

Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly

5 months ago talkbio0Tagged Alzheimer, Apolipoprotein E4, ARIA, authorization, Biogen, Eisai, Eli Lilly, EU, High, Kisunla, Leqembi, Restricted

Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High

Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives

5 months ago talkbio0Tagged 90%, Interleukin-2, Mural, Mural Oncology, Nemvaleukin Alfa, strategic alternatives

Interleukin-2, Mural Oncology, Mural, strategic alternatives, Nemvaleukin Alfa, 90%

Dexcom extends G7 sensor wear time to 15 days with latest FDA nod

5 months ago talkbio0Tagged Accurate (qualifier), Continuous glucose monitoring, day, Extension, MSH5 gene, sensor (device), United States Food and Drug Administration, wear time

United States Food and Drug Administration, sensor (device), Continuous glucose monitoring, MSH5 gene, Accurate (qualifier), Extension, wear time, day

The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring

5 months ago talkbio0Tagged 2025, Biopharma layoffs, Drug Industry, Galapagos layoffs, Gilead, Industry, losses, Merck, Myers, Novartis, Q1 2025, restructuring, Squibb Layoffs, trends qualifier

Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.

Pharma stocks swerve as Trump hits pause on most tariffs

5 months ago talkbio0Tagged Market, Pauses, Transplant Registry Unified Management Program

Market, Transplant Registry Unified Management Program, Pauses

Federal Judge Blocks NIH Grant Caps as HHS Appeals Ruling

5 months ago talkbio0Tagged Administration occupational activities, Administrative Procedure Act, appeal, CHARGE Syndrome, federal judge, Health Policy, Indirect, injunction, Legal, Medical Research activity, NIH Mouse, Permanent, research, Transplant Registry Unified Management Program, U.S., United States

NIH, HHS, research funding, grant caps, indirect costs, federal judge, permanent injunction, Trump administration, medical research, Administrative Procedure Act, legal appeal, U.S. healthcare policy.